AstraZeneca PLC (AZNL.XC)
| Previous close | 12,559.00 |
| Open | 12,575.00 |
| Bid | 12,628.00 x 0 |
| Ask | 12,632.00 x 0 |
| Day's range | 12,575.00 - 12,634.00 |
| 52-week range | 9,461.00 - 12,682.00 |
| Volume | |
| Avg. volume | 326,693 |
| Market cap | 195.798B |
| Beta (5Y monthly) | 0.17 |
| PE ratio (TTM) | 3,946.88 |
| EPS (TTM) | 3.20 |
| Earnings date | 25 Jul 2024 |
| Forward dividend & yield | 2.28 (1.82%) |
| Ex-dividend date | 22 Feb 2024 |
| 1y target est | N/A |
ReutersChina approves AstraZeneca's Tagrisso-chemo combo as first-line treatment
AstraZeneca said the approval by China's National Medical Products Administration (NMPA) was based on trials which showed that patients given the combination treatment lived without the disease getting worse longer than those given just Tagrisso. The median progression-free survival of patients treated with Tagrisso and chemotherapy was 25.5 months, 8.8 months more than those treated with just Tagrisso.
BenzingaAstraZeneca's Blockbuster Cancer Drug Imfinzi Flunks As Follow-Up In Type Of Early-Stage Lung Cancer, But Hits Primary Goal In Phase 3 Bladder Cancer Study
On Tuesday, AstraZeneca Plc (NASDAQ:AZN) released topline data from the ADJUVANT BR.31 Phase 3 trial, sponsored by the Canadian Cancer Trials Group. The data showed that Imfinzi (durvalumab) did not achieve statistical significance for the primary endpoint of disease-free survival versus placebo in early-stage non-small cell lung cancer (NSCLC) after complete tumor resection in patients whose tumors express PD-L1 on 25% or more tumor cells. “We are disappointed in the ADJUVANT BR.31 results,” sa
Business WireIMFINZI® (durvalumab) demonstrated statistically significant and clinically meaningful improvement in event-free survival and overall survival for muscle-invasive bladder cancer in NIAGARA Phase III trial
WILMINGTON, Del., June 25, 2024--Positive high-level results from the NIAGARA Phase III trial showed AstraZeneca’s IMFINZI® (durvalumab) in combination with chemotherapy demonstrated a statistically significant and clinically meaningful improvement in the primary endpoint of event-free survival (EFS) and the key secondary endpoint of overall survival (OS) versus neoadjuvant chemotherapy for patients with muscle-invasive bladder cancer (MIBC). Patients were treated with IMFINZI in combination wit
